Breastfeeding May Reduce Risk of Hormone Receptor-Negative Breast Cancers

Ever breastfeeding may provide a protective effect against hormone receptor (HR)-negative breast cancers.
Ever breastfeeding may provide a protective effect against hormone receptor (HR)-negative breast cancers.

Ever breastfeeding may provide a protective effect against hormone receptor (HR)-negative breast cancers, a meta-analysis published online ahead of print in the journal Annals of Oncology has shown.1

Although breastfeeding has been inversely associated with overall risk of breast cancer, this association may differ between breast cancer receptor statuses.

Therefore, a team of researchers led by Marisa Weiss, MD, president and founder of Breastcancer.org, sought to conduct a systematic review and meta-analysis of case-control and prospective cohort studies to evaluate the association between breastfeeding and breast cancer by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status.

Researchers analyzed 27 studies that included a total of 36,881 breast cancer cases. Results showed that ever breastfeeding was associated with a 10% reduction in the risk for developing ER-negative and PR-negative breast cancer when results were adjusted for various confounding factors.

Although based on a small number of studies, researchers found that breastfeeding was associated with an approximately 20% reduction in the risk for triple-negative breast cancer.

The meta-analysis demonstrated no significant association between ever breastfeeding and the risk of ER-positive and/or PR-positive breast cancer in cohort studies; however, several case-control studies showed an inverse relationship between breastfeeding duration and the risk for ER-positive and/or PR-positive breast cancers.

“The association between breastfeeding and receptor-positive breast cancers needs more investigation,” the authors conclude.

REFERENCE

1. Islami F, Liu Y, Jemal A, et al. Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysis [published online ahead of print October 26, 2015]. Ann Oncol. doi:10.1093/annonc/mdv379.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs